Astragalus Extract — The Telomerase Activator

The primary active compounds in Astragalus extract, particularly cycloastragenol and astragaloside IV, are purported to activate telomerase reverse transcriptase (TERT). Telomerase adds TTAGGG repeats to the ends of chromosomes, counteracting the telomere shortening that occurs with each cell division. By maintaining telomere length, these compounds may delay replicative senescence and preserve the proliferative capacity of stem cells and immune cells. Additionally, Astragalus exhibits broad anti-inflammatory and antioxidant effects, likely mediated through the modulation of NF-κB and Nrf2 pathways.

Human evidence for longevity specifically is limited but emerging. A proprietary Astragalus extract (TA-65) has been studied in small human trials, showing modest improvements in metabolic markers, immune system remodeling (e.g., decreased percentage of senescent cytotoxic T cells), and potential lengthening of critically short telomeres over a 1-year period. However, large-scale, long-term human trials demonstrating definitive lifespan extension or significant healthspan improvements are lacking.

Standardized extracts are typically dosed between 250–1,000 mg per day. For specific proprietary extracts like TA-65, doses range from 250 to 1,000 U (units) daily, often taken on an empty stomach. Traditional root powder doses are much higher (9–30 grams daily), but longevity protocols generally rely on concentrated extracts.

Astragalus is generally well-tolerated with a strong safety profile in traditional use. Mild adverse effects may include gastrointestinal upset. Due to its immune-stimulating properties, it should be used with caution in individuals with autoimmune diseases or those taking immunosuppressive medications. The long-term safety of chronic telomerase activation remains a theoretical concern regarding oncogenesis, though current data has not shown an increased cancer risk.

Key Papers